Mathematics against leukemias

Acute Lymphoblastic Leukemia is the most frequent cancer type in children. Although 80% of patients are cured with the standard treatment, a fraction of patients still relapse and die because of the disease. Standard treatment of the disease will be determined by patient risk group. We use mathematical modeling to improve patient stratification, identify relapse risk and design personalized treatments by better using the large amount of data available, with a special focus on flow cytometry data.

Additionally, we are currently working on pediatric B-ALL from a genomic perspective. We are trying to assess the role of aneuploidy and chromosomal instability in pediatric B-ALL initiation and progression. Understanding its dynamics from a computational point of view can help in patient stratification.




Mathematics against leukemias at MOLAB is developed in collaboration with Anna Marciniak-Czochra (Ruprecht-Karls-Universität Heidelberg), Helen Byrne (University of Oxford), Juan Luis Fernández-Martínez (University of Oviedo) and David Basanta (Moffitt Cancer Research Center). To this end, clinical, biological data and the extensive knowledge in Acute Lymphoblastic Leukemia is provided by our collaborators in different medical institutions: Hospital Universitario de Jerez de la Frontera (lead: Juan Francisco Rodríguez Gutiérrez), Hospital Universitario Virgen del Rocío (lead: Cristina Blázquez Goñi), Hospital Universitario Niño Jesús de Madrid (lead: Manuel Ramírez Orellana), Hospital Universitario La Paz de Madrid (lead: Antonio Pérez Martínez), Hospital Clínico Universitario Virgen de la Arrixaca de Murcia (lead: Jose Luis Fuster Soler), Hospital Universitario Reina Sofía de Córdoba (lead: Joaquín Sánchez García), Hospital Virgen de las Nieves (lead: Gema Salas Camacho), Institut de Recerca Contra la Leucèmia Josep Carreras (lead: Eulàlia Genescà Ferrer). Moreover, experimental data and extensive knowledge on chromosomal instability and aneuploidies are provided by Óscar Molina and Pablo Menendez (Josep Carreras Leukemia Research Institute).